VSIR and prostate cancer: The expression of VISTA on tumor-infiltrating T cells and TAMs was elevated in prostate cancer and melanoma patients following ipilimumab treatment, with a greater proportion of macrophages with VISTA expression being of the immunosuppressive M2 phenotype, suggesting that VISTA may represent a compensatory resistance mechanism [38].